Permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations

Summary

The bill amends state drug‑control statutes so that any crystalline polymorph psilocybin product that the FDA approves and the DEA moves out of Schedule I can be legally prescribed and sold. It directs the West Virginia Board of Pharmacy to oversee schedule recommendations and to act on emergencies when the FDA and DEA provide guidance. This change affects physicians, pharmacists, manufacturers and patients seeking therapeutic psilocybin.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share